Prescriber Scope of Practice for Weight Loss/GLP-1 in North Carolina

If you’re a psychiatrist or psychiatric nurse practitioner wondering whether you can legally prescribe weight-loss medications—especially the buzzy GLP-1 drugs like semaglutide (Wegovy/Ozempic) or tirzepatide (Mounjaro/Zepbound)—via telehealth, you’re not alone. The obesity treatment space is exploding, and the rules governing who can prescribe what, where, and how are a patchwork of federal waivers, state-specific regulations, and scope-of-practice questions that change faster than most of us can keep up.

Here’s the reality: Yes, psychiatrists (MDs/DOs) can legally prescribe weight-loss medications including GLP-1s via telehealth in most states, but there are significant regulatory guardrails you need to know. For PMHNPs and psychiatric PAs, the answer gets murkier—you’re often in a gray zone where your mental health-focused scope of practice collides with obesity treatment, and state regulations on supervision and specialty certification come into play.

This isn’t theoretical. Primary care doctors are already raising red flags about telehealth weight-loss services—over half express concerns about ‘clinically inappropriate prescribing’ and poor continuity of care from online platforms. If you’re thinking about adding weight management to your practice or joining a telehealth platform that offers it, you need to understand both the business opportunity and the compliance risks.

Let’s break down what you actually need to know.

The Federal Picture: DEA Rules and Controlled Substances

The Ryan Haight Act and COVID-Era Flexibilities

Under normal federal law (the Ryan Haight Online Pharmacy Act), prescribing controlled substances via telehealth requires at least one in-person medical evaluation first. During COVID, that requirement was waived. Here’s where we stand now:

The DEA has extended telehealth prescribing flexibilities through December 31, 2026. This means you can currently prescribe controlled substances (like phentermine, a Schedule IV appetite suppressant commonly used for weight loss) to new patients via telehealth without an initial in-person visit—but this is explicitly temporary.

The DEA is drafting permanent rules that will likely require either a ‘special telemedicine registration’ or impose limits like initial 30-day supplies for certain controlled drugs. They’re seeking public comment on whether to restrict tele-prescribing Schedule II medications (think Adderall for ADHD, though less relevant for weight loss) to providers in the same state as the patient, and potentially capping what percentage of your practice can be telehealth-only.

Bottom line: If you’re prescribing controlled weight-loss meds (phentermine, diethylpropion) via telehealth right now, you’re operating under a temporary federal allowance that ends in 2026. Build your practice with the assumption that you’ll need to adapt when permanent rules arrive.

GLP-1s Are Different (and Easier)

Here’s the good news: GLP-1 agonists like semaglutide and tirzepatide are NOT controlled substances. They’re not subject to DEA restrictions at all. From a federal standpoint, you can prescribe Wegovy or Mounjaro via telehealth to a new patient you’ve never met in person, as long as you meet the standard of care for prescribing any medication remotely.

That standard typically means:

• Conducting a proper clinical evaluation (usually via live video)
• Reviewing the patient’s medical history and current medications
• Documenting appropriate indications (BMI ≥30 or ≥27 with comorbidities for FDA-approved weight loss use)
• Providing informed consent about risks, benefits, and alternatives
• Establishing a plan for follow-up and monitoring

No DEA registration needed for GLP-1s. No special waivers. Just good clinical practice.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-by-State Rules: Where It Gets Complicated

Federal law sets the floor, but states can impose stricter requirements. Here’s what psychiatrists need to know about the priority states:

New York: The Strictest Standard

New York requires an in-person medical evaluation before prescribing ANY controlled substance to a new patient, with very limited exceptions. This applies to phentermine and any other controlled weight-loss medications.

The exceptions are narrow:

• Another New York provider examined the patient in person within the past 12 months and shared records
• You’re covering for a colleague who saw the patient face-to-face
• It’s an emergency for an existing patient (maximum 5-day supply)

What this means: If you’re a New York-based psychiatrist wanting to prescribe phentermine via telehealth, you either need to see the patient in person first, or coordinate with another provider who has. For GLP-1s (non-controlled), you’re fine—telehealth evaluation is sufficient.

New York also mandates checking the state Prescription Monitoring Program (PMP) within 24 hours before prescribing any Schedule II-IV controlled substance, and all prescriptions must be sent electronically.

Florida: Permissive but Prescriptive

Florida is telehealth-friendly but has specific obesity treatment standards that apply to all physicians:

• Patients must have BMI ≥30 (or ≥27 with comorbidities) or documented body fat percentages above threshold
• You must obtain written informed consent explaining risks of weight-loss medications
• You must re-evaluate the patient at least every 3 months while on anti-obesity meds
• You’re required to provide a ‘Weight-Loss Consumer Bill of Rights’ to each patient

Florida prohibits teleprescribing Schedule II controlled substances (with exceptions for psychiatric disorders—more on that below), but phentermine is Schedule IV, so telehealth prescribing is allowed. You must check Florida’s E-FORCSE PDMP before prescribing any controlled substance to patients 16 and older.

Importantly for psychiatrists: Florida carved out an exception allowing telehealth prescribing of Schedule II medications for psychiatric treatment. So you can prescribe Adderall for ADHD via telehealth, but not amphetamines for weight loss (though those are rarely used anymore anyway).

California: Corporate Practice Concerns

California allows telehealth prescribing with no blanket in-person requirement. The key compliance points:

• Must obtain and document patient consent for telehealth
• Must check the CURES PDMP before first prescription of any Schedule II-IV drug and at least every 4 months for ongoing therapy
• All prescriptions must be electronic

The bigger issue in California is the Corporate Practice of Medicine (CPOM) doctrine. Medical services must be provided by physician-owned entities or compliant management service organizations. If you’re thinking about joining or starting a telehealth weight-loss company, the ownership structure matters—non-physicians can’t independently operate a medical clinic in California.

Also noteworthy: California’s Medi-Cal (Medicaid) will stop covering GLP-1 medications for weight loss as of January 2026, classifying them as non-covered. This will likely push more patients toward cash-pay telehealth models.

Texas: Coordination Required

Texas has no in-person exam requirement for telehealth prescribing. You can prescribe phentermine or GLP-1s remotely after a proper video evaluation.

However, Texas requires telehealth providers to:

• Provide follow-up care instructions
• Send a report to the patient’s primary care provider within 72 hours (with patient consent)
• Check the Texas PMP for controlled substances (mandatory for opioids and benzos; best practice for all controlled meds)

Texas NPs and PAs must have a Prescriptive Authority Agreement with a physician to prescribe anything, including weight-loss medications. There’s no independent practice for NPs in Texas.

Pennsylvania and Illinois: Federal Rules Apply

Neither state has imposed state-specific in-person requirements beyond the federal standard. Under the current DEA extension, you can prescribe controlled weight-loss medications via telehealth in both states.

Pennsylvania requires checking the PA PDMP before prescribing opioids or benzos (each time), and recommends it for other controlled substances. CRNPs need collaborative agreements with physicians.

Illinois is progressive—experienced APRNs can achieve Full Practice Authority after 4,000 hours and additional training, allowing them to prescribe independently (including controlled substances). Illinois allows both video and audio-only telehealth, though video is prudent for weight-loss evaluations.

Scope of Practice: Can Psychiatrists Treat Obesity?

For Psychiatrists (MD/DO)

Legally, yes. You hold an unrestricted medical license. There’s no separate ‘obesity license’ requirement. You can prescribe FDA-approved weight-loss medications or use GLP-1s off-label, just like you can manage hypertension or prescribe metformin for pre-diabetes.

Practically, it’s about competence. Medical boards will hold you to the same standards they’d hold any physician treating obesity:

• Appropriate patient evaluation (history, exam, labs if indicated)
• Documentation of BMI and qualifying comorbidities
• Informed consent about risks (cardiovascular effects, GI side effects, contraindications)
• Evidence of behavioral counseling (diet, exercise) or referral to nutrition specialists
• Regular monitoring and follow-up

Some states make this explicit. Florida’s rules on obesity prescribing apply to ‘each physician’—whether you’re a bariatrician or a psychiatrist moonlighting in weight loss, you’re held to the same documentation standards.

The business case: Many psychiatrists already encounter weight management issues tangentially—patients gaining weight on antipsychotics, binge eating disorder, depression affecting self-care. You might prescribe a GLP-1 to mitigate medication-induced weight gain or as part of integrated mental health and metabolic care. That’s legitimate medical practice.

Where you need to be careful: Don’t practice outside your actual knowledge base. If you’re going to manage GLP-1 therapy long-term, you should understand titration protocols, managing side effects like nausea and pancreatitis risk, when to check lipase or amylase levels, contraindications in patients with thyroid cancer history or gastroparesis, etc. Some psychiatrists pursue additional certification in Obesity Medicine (American Board of Obesity Medicine) to bolster credibility and competence.

For Psychiatric NPs and PAs

This is where scope gets tricky. Your license and certification are in mental health, not obesity medicine or primary care.

Most state nursing boards define scope of practice as what a ‘reasonably prudent practitioner with similar training and certification’ would do. A PMHNP’s training covers psychiatric assessment and psychotropic medication management. Treating obesity—especially prescribing medications purely for weight loss—could be seen as outside that scope unless:

1. You have additional training or certification in weight management/obesity medicine
2. You’re practicing under physician supervision/collaboration with a physician who has obesity expertise (not just a psychiatrist collaborating on mental health)
3. It’s integrated into mental health treatment—e.g., managing weight gain from psych meds, treating binge eating disorder with both therapy and medication

In states like Texas and Florida, NPs need physician collaboration to prescribe, period. If you’re a PMHNP in those states wanting to offer weight-loss treatment, your collaborating physician should ideally be a family medicine or internal medicine doc with obesity management in their scope. A psychiatrist collaborating with you on weight loss might raise eyebrows unless they have relevant expertise.

In California and New York, experienced NPs can practice more independently (California’s AB 890 allows independent practice for qualified NPs as of 2026; New York allows it after 3,600 supervised hours). Even with that autonomy, you’re expected to stay within your clinical competence. Opening a weight-loss clinic as a PMHNP when your certification and experience are purely psychiatric could be professionally risky.

The safer path for NPs: Either pursue additional certification (ANCC’s Adult-Gerontology Primary Care NP, or a post-master’s certificate in obesity management), or structure your practice explicitly around the mental health aspects of weight management—medication-induced weight gain, eating disorders, motivational interviewing for lifestyle change—and refer or collaborate for the purely metabolic/endocrine management.

The Economics: Why Platforms Like Klarity Make Sense

Let’s talk about the real cost of acquiring weight-loss patients if you go solo:

The DIY Marketing Reality

Building a weight-loss practice from scratch through traditional marketing channels is expensive and uncertain:

• SEO: Takes 6-12 months of consistent investment before you see meaningful patient volume. You’re competing with established clinics, hospital systems, and venture-backed telehealth companies. Most solo psychiatrists don’t have the expertise or patience for this.

• Google Ads: Mental health and weight-loss keywords cost $15-40+ per click. Most clicks don’t convert to booked patients. Realistic cost per booked patient through PPC is $200-400+ when you factor in click costs, landing page optimization, and conversion rates.

• Directory listings: Psychology Today, Zocdoc, etc. charge monthly fees ($100-300+) and you’re competing with hundreds of providers on the same search results page. Zocdoc charges per booking ($35-100+). Total monthly cost adds up.

When you add up agency/consultant fees, ad spend testing, staff time handling and qualifying leads, no-show rates from cold leads, and failed campaigns, the all-in cost to acquire a qualified psychiatric or weight-loss patient through DIY marketing is $200-500+. And that’s assuming you eventually figure out what works.

The Klarity Model: Pay Only for Patients You Actually See

Instead of gambling $3,000-5,000/month on marketing with uncertain ROI, Klarity uses a pay-per-appointment model:

• No upfront marketing spend or monthly subscription fees
• No wasted ad spend on clicks that don’t convert
• Pre-qualified patients already matched to your specialty and availability
• Built-in telehealth infrastructure (no separate platform costs)
• Both insurance and cash-pay patient flow
• You control your schedule—only pay when you see patients

Klarity handles patient acquisition, credentialing, billing infrastructure, and compliance support. You pay a standard listing fee per new patient lead, but unlike traditional marketing, you only pay when a qualified patient actually books with you. That’s guaranteed ROI versus gambling on marketing channels.

For psychiatrists expanding into weight management or PMHNPs working under appropriate supervision, a platform that removes patient acquisition risk entirely makes economic sense—especially while you’re building expertise and figuring out what patient volume you can sustainably manage.

Practical Compliance Checklist

If you’re going to prescribe weight-loss medications via telehealth, here’s your compliance foundation:

Universal Requirements

Licensure:

• Must be licensed in the state where the patient is physically located at the time of the visit
• Consider Interstate Medical Licensure Compact if practicing in multiple states

Patient Evaluation:

• Live video visit (audio-only generally insufficient for initial weight-loss evaluation)
• Document: BMI, weight history, previous weight loss attempts, diet/exercise habits, medical comorbidities
• Review contraindications (pregnancy, thyroid cancer history for GLP-1s, cardiovascular disease for stimulants)
• Check for eating disorders or psychiatric conditions that need addressing first

Informed Consent:

• Explain risks, benefits, alternatives
• Document that patient understands this is long-term management, not a quick fix
• Many states require written consent specifically for telehealth and/or weight-loss treatment

Follow-Up:

• GLP-1s: Monthly initially for dose titration and side effect monitoring, then at least quarterly
• Phentermine: Monthly (it’s typically prescribed short-term anyway, 12 weeks or less)
• Check the state requirement—Florida mandates quarterly minimum; other states may require more frequent

PDMP Checks:

• For controlled substances (phentermine, etc.), check your state’s prescription monitoring database before prescribing
• Document the check in your note
• Frequency varies by state (every prescription in NY; first time and periodically in others)

E-Prescribing:

• Required in most states for controlled substances (NY, CA, IL, FL, etc.)
• Use a certified EPCS (Electronic Prescribing for Controlled Substances) system

State-Specific Add-Ons

Florida:

• Written informed consent required
• Provide ‘Weight-Loss Consumer Bill of Rights’
• Quarterly re-evaluation minimum
• Don’t prescribe SSRIs off-label for weight loss (explicitly prohibited by FL rule)

California:

• Document telehealth consent
• Check CURES every 4 months for ongoing controlled substance therapy
• Ensure ownership structure complies with CPOM

New York:

• If prescribing controlled substances, ensure in-person exam or qualifying exception
• Check PMP within 24 hours before prescribing Schedule II-IV

Texas:

• Send report to patient’s PCP within 72 hours (with consent)
• NPs/PAs need explicit delegation for weight-loss prescribing in their agreement

FAQ: What Providers Are Actually Asking

Can I prescribe GLP-1 medications via telehealth to new patients legally?

Yes, in almost all states, because GLP-1s (semaglutide, tirzepatide) are not controlled substances. You need a proper telehealth evaluation that meets the standard of care (live video, appropriate history and exam), documentation of indications (BMI ≥30 or ≥27 with comorbidities), informed consent, and a follow-up plan. Check your specific state’s telehealth requirements—some mandate patient consent documentation or specific record-keeping.

Do I need an in-person visit to prescribe phentermine online?

Depends on your state:

• New York: Yes, in-person exam required (with narrow exceptions)
• Texas, Florida, California, Pennsylvania, Illinois: No, under current federal DEA extension through 2026, you can prescribe via telehealth after appropriate evaluation
• All states: You must check the state PDMP and follow controlled substance prescribing protocols

Once the DEA’s temporary extension ends in 2026, federal rules may reimpose in-person requirements or require special registration.

As a PMHNP, can I offer weight-loss treatment?

Usually requires physician collaboration or additional certification, since treating obesity may be outside a psychiatric NP’s usual scope of practice. Your state nursing board expects you to practice within your training.

Options:

• Work under supervision/collaboration with a physician who has obesity medicine expertise
• Pursue additional certification in obesity management or primary care
• Focus on the mental health aspects (medication-induced weight gain, eating disorders) and coordinate with primary care for metabolic management

In states with independent NP practice (CA, NY after 3,600 hours, IL with Full Practice Authority), you have more autonomy but are still expected to practice within your competence area.

What about compounded semaglutide?

This is a minefield. The FDA has raised safety concerns about compounded GLP-1s from telehealth clinics. Compounding is only legal when there’s a drug shortage (which existed for semaglutide in 2023-24 but is resolving) or a specific patient need for customization.

If you’re prescribing compounded semaglutide:

• Ensure the compounding pharmacy is FDA-registered and follows USP standards
• Document why the FDA-approved product isn’t appropriate for this patient
• Be aware that primary care doctors are skeptical—over half express concerns about compounded GLP-1 safety from online providers

Many insurers won’t cover compounded versions, so this is usually cash-pay, which raises its own ethical questions about access and affordability.

What happens when the DEA extension expires in 2026?

No one knows exactly yet—the DEA is drafting permanent rules. Likely scenarios:

• Special telemedicine registration required to prescribe controlled substances remotely
• Initial supply limits (e.g., 30-day max for new telehealth patients)
• State-specific restrictions maintained or expanded

What you should do now:

• Don’t build your entire practice model around controlled substance prescribing via telehealth unless you’re prepared to pivot
• Focus on GLP-1s and other non-controlled options for long-term sustainability
• Stay connected to professional organizations (APA, ASAM, etc.) that will advocate during the rulemaking process

The Bottom Line: Opportunity with Guardrails

Can psychiatrists prescribe weight-loss medications via telehealth? Yes—but it’s not a regulatory free-for-all.

You have broad legal authority to treat obesity as a physician, and the business opportunity is real. Obesity rates are rising, GLP-1 demand is exploding, and many patients prefer the convenience of telehealth over in-person visits to a specialty clinic.

But you also have real compliance obligations:

• Know your state’s specific rules (in-person requirements, PDMP checks, prescribing standards)
• Practice within your competence (additional training if you’re making this a significant part of your practice)
• Document appropriately (informed consent, follow-up plans, standard-of-care evaluations)
• Coordinate care (work with patients’ primary care providers, especially for complex cases)

For PMHNPs, the path is narrower—you’ll likely need physician collaboration and should be thoughtful about scope of practice boundaries.

The economic case for joining a platform like Klarity is straightforward: instead of spending months and thousands of dollars on marketing with uncertain results, you pay only when you see qualified patients. That removes the financial risk of practice expansion and lets you focus on clinical care while the platform handles patient acquisition, credentialing, and infrastructure.

Ready to explore adding weight management to your practice through Klarity? We provide the patient flow, telehealth platform, and compliance support—you provide the clinical expertise. Learn more about joining Klarity’s provider network →

Sources and References

1. U.S. Department of Health & Human Services – Press Release: ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026’ (January 2, 2026). Official DEA/HHS policy statement. www.hhs.gov

2. Florida Statutes § 456.47 – Use of Telehealth to Provide Services (Florida Telehealth Act, 2019). Official state statute governing telehealth in Florida. florida.public.law

3. Florida Administrative Code 64B8-9.012 – ‘Standards for the Prescription of Drugs to Treat Obesity’ (Effective August 8, 2022). Official Florida Board of Medicine rule outlining obesity prescribing requirements. regulations.justia.com

4. Goodwin Law – Client Alert: ‘A Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs’ (March 30, 2024). Detailed legal analysis of state rules for weight-loss prescribing. www.goodwinlaw.com

5. California Medical Association – ‘GLP-1 medications for weight loss will no longer be covered by Medi-Cal’ (December 2, 2025). Official announcement of California Medicaid coverage changes. www.cmadocs.org

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,disruptions%20in%20care%20while%20permanent
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,FDA%2C%20pharmacy%2C%20and%20board%20alerts
• https://www.cchpca.org/topic/online-prescribing/#:~:text=No%20controlled%20substance%20shall%20be,for%20the%20medical%20evaluation%2C%20and
• https://florida.public.law/statutes/fla.stat.456.47#:~:text=provider%20is%20not%20required%20to,is%20prescribed%20for%20the%20following
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=Florida%20law%20restricts%20the%20prescribing,5
• https://www.ofdigitalinterest.com/2023/09/weight-loss-programs-in-florida-state-law-considerations-for-glp-1-telehealth-providers/#:~:text=2000%20%28Fla,loss%20providers%20are%20required%20to
• https://www.medicaldirectorco.com/california-weight-loss-clinic-and-telehealth-compliance-guide-2025/#:~:text=medical%20director%20and%20retain%20full,Clinics%20must%20maintain%20DEA
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,require%20DEA%20registration
• https://www.fiercehealthcare.com/providers/primary-care-doctors-concerned-about-patient-risks-telehealth-prescribers-glp-1s-survey#:~:text=Primary%20care%20physicians%20are%20mainly,cited%20by%20half%20of%20physicians
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated